Novo Nordisk, Vivtex Collaborate on Oral Biologics for Obesity, Diabetes

MT Newswires Live02-25

Novo Nordisk (NVO) has entered into a partnership with Vivtex to develop oral biologics for obesity, diabetes and related conditions using Vivtex's drug delivery technologies, the companies said Wednesday.

Under the agreement, Vivtex is entitled to receive up to $2.1 billion in upfront payment, research funding, and milestone payments, as well as royalties on future product sales, according to a statement.

Vivtex will license certain technologies to Novo Nordisk, which will global development, regulatory, manufacturing and commercialization activities, the companies said.

Shares of Novo Nordisk were down 2% in recent premarket activity Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment